Hospitalization-related bone loss and the protective effect of risedronate

Osteoporosis International

Volumn 17, Issue 2, 2006, Pages 212-216

  Heaney, Robert P ^a   Valent, David J ^b   Barton, Ian P ^a  

^a CREIGHTON UNIVERSITY   (United States)

^b PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

Age related bone loss; Antiresorptives; Bisphosphonates; Bone mineral density; Medical surgical illness; Risedronate

Indexed keywords

RISEDRONIC ACID;

AGED; ARTICLE; BODY HEIGHT; BODY WEIGHT; BONE DENSITY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DATA ANALYSIS; EXPERIENCE; FEMUR TROCHANTERIC FRACTURE; FRACTURE; GALLBLADDER DISEASE; HEART INFARCTION; HIP; HOSPITALIZATION; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; OSTEOLYSIS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN CANCER; SPINE; UNSPECIFIED SIDE EFFECT;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE RESORPTION; ETIDRONIC ACID; FEMALE; FEMUR; HOSPITALIZATION; HUMANS; LUMBAR VERTEBRAE; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 30144438104     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-005-1975-4     Document Type: Article

References (17)

1. Whedon GD, Heaney RP (1991) Effects of physical inactivity, paralysis, and weightlessness. In: Hall B (ed) Bone, vol. 7. CRC Press, Boca Raton, FL, USA, pp 57-77
2. Donaldson CL, Hulley SB, Vogel JM, Hattner RS, Bayers JH, McMillan DE (1970) Effect of prolonged bed rest on bone mineral. Metabolism 19:1071-1084
3. LeBlanc AD, Schneider VS, Evans HJ, Engelbretson DA, Krebs JM (1990) Bone mineral loss and recovery after 17 weeks of bed rest. J Bone Miner Res 5:843-850
4. Krølner B, Toft B (1983) Vertebral bone loss: an unheeded side effect of therapeutic bed rest. Clin Sci 64:537-540
5. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY for the Hip Intervention Program Study Group (2001) Effect of risedronate on the risk of hip fracture in elderly women. New Engl J Med 344:333-340
6. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD for the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group (1999) Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA 282:1344-1352
7. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R for the Vertebral Efficacy with Risedronate Therapy (VERT) Study Group (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established post-menopausal osteoporosis. Osteoporos Int 11:83-91
8. McClung M, Bensen W, Bolognese M, Bonnick S, Ettinger M, Harris S, Knecht T, Lang R, Miller P, Pavlov E, Silverman S, Woodson G, Faulkner K, Ethgen D, Axelrod D (1998) Risedronate increases bone mineral density at the hip, spine and radius in postmenopausal women with low bone mass [Abstract]. Osteoporos Int 8 [Suppl 3]:111
9. Fogelman I, Ribot C, Smith R, Ethgen D, Sod E, Reginster JY (2000) Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 85:1895-1900
10. Soininvaara TA, Jurvelin JS, Miettinen HJA, Suomalainen OT, Alhava EM, Kroeger PJ (2002) Effect of alendronate on periprosthetic bone loss after total knee arthroplasty: a 1-year, randomized, controlled trial of 19 patients. Calcif Tissue Int 71:472-477
11. LeBlanc AD, Driscol TB, Shackelford LC, Evans HJ, Rianon NJ, Smith SM, Feeback DL, Lai D (2002) Alendronate as an effective countermeasure to disuse induced bone loss. J Musculoskelet Neuronal Interact 2:335-343
12. Van der Poest Clement E, Patka P, Vandormael K, Haarman H, Lips P (2000) The effect of alendronate on bone mass after distal forearm fracture. J Bone Miner Res 15:586-593
13. Ruml LA, Dubois SK, Roberts ML, Pak CYC (1995) Prevention of hypercalciuria and stone-forming propensity during prolonged bed rest by alendronate. J Bone Miner Res 10:655-662
14. Chappard D, Minaire P, Privat C, Berard E, Mendoza-Sarmiento J, Tournebise H, Basle MF, Audran M, Rebel A, Picot C, Gaud C (1995) Effects of tiludronate on bone loss in paraplegic patients. J Bone Miner Res 10:112-118
15. Chappard D, Alexandre C, Palle S, Vico L, Morukov BV, Rodionova SS, Minaire P, Riffat G (1989) Effects of a bisphosphonate (1-hydroxy ethylidene-1,1 bisphosphonic acid) on osteoclast number during prolonged bed rest in healthy humans. Metab Clin Exp 38:822-825
16. Minaire P, Depassio J, Berard E, Meunier PJ, Edouard C, Pilonchery G, Goedert G (1987) Effects of clodronate on immobilization bone loss. Bone 8 [Suppl 1]:S63-S68
17. Lockwood DR, Vogel JM, Schneider VS, Hulley SB (1975) Effect of the diphosphonate EHDP on bone mineral metabolism during prolonged bed rest. J Clin Endocrinol Metab 41:533-541